Cell and gene therapy accelerator ElevateBio continues to refine ‘sweet spot’ with $525M series C

With a $525 million series C round led by Matrix Capital Management, ElevateBio will continue to home in on its sweet spot as a company builder, investor and strategic partner.

When ElevateBio LLC launched in 2019 with $150 million and a management team led by veterans from Alexion Pharmaceuticals Inc. and bluebird bio Inc. (NASDAQ:BLUE), the idea was to build a portfolio of gene and cell therapy companies with access to fully integrated process development and manufacturing capacity...